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ABSTRACT  
It has been previously demonstrated that the bi-directional transporter Na+/Ca2+ exchanger 
(NCX) working in the reverse (Ca2+-influx) - mode promotes the activation of ERK1/2 in 
response to the key pro-angiogenic cytokine VEGF in human endothelial cells (ECs).  
However, the molecular event(s) that elicit NCX reversal in VEGF-stimulated ECs remain 
unclear. Here we investigated whether Na+ influx via the diacylglycerol (DAG) – activated 
non-selective cation channel TRPC3 was functionally associated with NCX and whether its 
activity was required for VEGF-induced ERK1/2 activation and angiogenesis. We provide 
evidence that TRPC3 inhibitors and siRNA attenuated ERK1/2 phosphorylation, reduced 
PKCα activity and partially suppressed Ca2+ transients in response to VEGF. Additionally, 
TRPC3 inhibitors and siRNA significantly suppressed endothelial tubular differentiation, an in 
vitro indicator of angiogenesis.  We also report that simulating PLCγ activation downstream 
of VEGF receptor 2 by application of the cell-permeable DAG analogue 1-Oleoyl-2-acetyl-sn-
glycerol (OAG) was sufficient to activate ERK1/2 and enhance tubular differentiation. OAG-
induced ERK1/2 activation and tubulogenesis were significantly suppressed by TRPC3 and 
reverse-mode NCX inhibitors and siRNA. Moreover, whilst both reverse-mode NCX and 
TRPC3 inhibitors attenuated OAG-induced Ca2+ transients, only TRPC3 antagonists blunted 
Na+ influx in response to OAG. Importantly, when Na+ was increased in ECs by inhibiting the 
Na+-K+-ATPase, TRPC3 activity was dispensable for OAG-induced ERK1/2 phosphorylation.  
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Collectively, our research suggests that DAG generation downstream of VEGF receptors 
activatesTRPC3 causing Na+ influx with subsequent reversal of NCX, ERK1/2 activation and 
ultimately contributes to enhanced angiogenesis. Targeting reverse-mode NCX and its 
upstream initiator TRPC3 could be clinically relevant in conditions characterised by abnormal 
VEGF signalling.  
ABBREVIATIONS 
BAPTA-AM: 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
tetrakis(acetoxymethyl ester) 
CRAC: Ca2+-Release Activated Ca2+ Channel  
[Ca2+]i: Cytosolic Ca
2+ concentration  
DAG: Diacylglycerol 
EC: Endothelial Cell 
eNOS: Endothelial Nitric Oxide Synthase  
ERK1/2: Extracellular Regulated Kinase 1/2 
ECM: Extracellular Matrix Components 
GPCRs: G-protein coupled receptors 
MAPKs: Mitogen-Activated Protein Kinases 
miRNA: micro RNA 
NCX: Na+/Ca2+ exchanger 
OAG: 1-oleoyl-2-acetyl-sn-glycerol  
PI3K: Phosphoinositol-3-kinase 
PKC: Protein Kinase C  
PLCγ1: Phospholipase Cγ1  
PMA: Phorbol 12-myristate 13-acetate 
PMCA: Plasma membrane Ca2+ ATPase 
RTKs: Receptor Tyrosine Kinases 
siRNA: Short-interfering RNA 
TG: Thapsigargin  
SERCA: Sarcoendoplasmic Reticulum Ca2+-ATPase 
TREK: TWIK – related K+ channels 
TRPC3: Transient Receptor Potential Canonical 3  
VEGF: Vascular Endothelial Growth Factor 
VGCCs: Voltage-Gated Ca2+ Channels  
VGSCs: Voltage-Gated Na+ Channels  
1. Introduction 
Dysregulated angiogenesis is detrimentally involved in the progression of many 
pathophysiological conditions including, but not limited to, diabetic retinopathy, 
atherosclerosis and aggressive tumour growth [1], [2].  
 Vascular endothelial growth factor-Α (VEGF thereafter), the best studied and most 
prominent pro-angiogenic cytokine is necessary for endothelial cell (EC) survival under 
physiological conditions. Abnormal VEGF signalling has also been implicated in the 
excessive neo-angiogenesis associated with the progression of numerous diseases 
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including neoplastic expansion and dissemination [1], [2]. Therapeutic strategies targeting 
the VEGF signalling axis have been approved for a number of malignancies [2]. However, 
despite the enormous progress in understanding angiogenesis in preclinical tumour models, 
clinical response to anti-angiogenic therapy is variable and patients generally relapse within 
a year [3], [4]. Better understanding of endothelial VEGF signalling could therefore 
potentially improve clinical outcomes.  
In adults, VEGF primarily signals by binding to endothelial VEGFR2 (KDR/Flk1) 
receptors leading to receptor dimerization and VEGFR2 activation via trans-tyrosine 
autophosphorylation [5]. The subsequent activation of signalling cascades involving 
phosphoinositol-3-kinase (PI3K), Src kinase and phospholipase Cγ1 (PLCγ1)5 reprograms 
the endothelium for angiogenesis by facilitating the complex interaction of downstream 
effectors such as endothelial nitric oxide synthase (eNOS), protein kinases C (PKCs) and 
mitogen-activated protein kinases (MAPKs) [5].  
The extracellular regulated kinases 1 and 2 (ERK1/2) MAPKs, activated downstream 
of VEGFR2 in a PKC - dependent manner [6] have been shown to regulate the angiogenic 
response by controlling EC permeability [7], tubular differentiation [8] and more recently 
micro RNA (miRNA) expression [9].  
VEGF-activated ECs also demonstrate a biphasic increase in cytosolic Ca2+ 
concentration ([Ca2+]i) comprising an initial transient phase, attributed to Ca
2+ release from 
internal stores, followed by a sustained influx of Ca2+ from the extracellular milieu [10], [11], 
[12]. Targeting Ca2+ signalling in EC is emerging as a viable alternative strategy to VEGF 
receptor inhibition in controlling dysregulated angiogenesis and tumour vascularisation [13]. 
In particular, Ca2+ influx through the canonical transient receptor potential channels TRPC6 
[14], [15], [16], TRPC3 [17] and the pore-forming subunit of the Ca2+-release activated Ca2+ 
channel (CRAC), Orai1 [18] have all been implicated in VEGF-induced angiogenesis.   
We have also reported that Ca2+ influx through the mammalian transporter Na+/Ca2+ 
exchanger (NCX) contributed to VEGF-induced human umbilical vein EC (HUVEC) 
angiogenic properties by modulating ERK1/2 activation in a PKC-dependent manner [11]. 
The mammalian NCX comprises 3 genes (NCX1 to NCX3) and extrudes cytosolic Ca2+ in 
exchange for extracellular Na+ when operating in the so-called forward mode. Alternatively, 
depending on transmembrane [Ca2+] and [Na+] and the membrane potential, they can 
operate in the reverse-mode extruding Na+ and leading to Ca2+ influx [19]. The primary 
physiological role of NCX is to maintain a low cytosolic [Ca2+] working in the forward (Ca2+- 
efflux) mode particularly in excitable cells [19]. Nonetheless, Na+ overload and/or plasma 
membrane depolarisation, typified during ischaemia–reperfusion, could lead to the reversal 
of the exchanger, subsequent Ca2+ overload and cellular injury [20].  Active NCX has been 
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reported in the endothelium [21], [22] and the splice variants of the cardiac isoform NCX1.3 
and NCX1.7 are believed to be the predominant NCX species present in ECs [23].  
In our previous studies [11] we showed that acute Na+ loading of HUVECs promoted 
VEGF-induced ERK1/2 activation and proposed that associated Na+-influx pathway(s) along 
with the control of the membrane potential by voltage-gated Na+ channels (VGSCs) [10], 
could be reversing NCX into the Ca2+-influx mode in response to VEGF. In the present study 
we investigated whether one of those Na+ mechanisms could be the non-selective cation 
channel TRPC3 which is known to associate with NCX [24] and to control endothelial 
angiogenesis [17]. 
2. Materials and Methods 
2.1. Materials 
Human recombinant VEGF (V5765), 1-Oleoyl-2-acetyl-sn-glycerol (OAG; O6754), BAPTA-
AM (A1076), Ouabain (O3125), Ionomycin (I0634), Nifedipine (N7634) and Phorbol 12-
myristate 13-acetate (PMA; P1585) were from Sigma-Aldrich. Pyr3 (648490), Pyr6 (203891), 
Pyr10 (648494) and EGTA-AM (324628) were from Merck Millipore. PD98050 (1213), SN-6 
(2184) and Gӧ6983 (2285) were from Tocris. SEA0400 (HY-15515) was from MedChem 
Express. All other chemicals used in this study were from Sigma-Aldrich unless stated 
otherwise.  
2.2. Cell culture and protein extraction 
HUVECs from pooled donors were purchased from TCS Cellworks (ZHC-2102) and were 
cultured in Human Large Vessel Endothelial Cell Basal Medium containing growth 
supplement and antibiotics (Amphotericin B/Gentamycin) also from TCS Cellworks (ZHM-
2953) as previously described [10], [11], [25]. HUVEC monolayers at approximately 80% 
confluency were subcultured using TrypLETM Express enzyme containing phenol red from 
ThermoFisher Scientific (12605010). In the present study cells between passages 3-9 were 
used. 
 For VEGF and OAG stimulation assays, approximately 100,000 cells plated in 35mm 
x 10mm dishes (Corning®; 353801) were washed twice with PBS and subsequently serum-
starved for 1h in a physiological buffer containing 144 mM NaCl, 5.4 mM KCl, 2.5 mM CaCl2, 
1 mM MgCl2, 5.6 mM D-glucose, and 5 mM Tris-HCl, pH 7.4, at 37°C. Cells were pre-
incubated with inhibitors or vehicle for 30min prior to the addition of VEGF or OAG. HUVECs 
were challenged with 50ng/ml VEGF or 100μM OAG at 37oC for the times indicated in the 
Figure legends. The stimulation was terminated by washing HUVECs once with ice-cold 
PBS and subsequent application of lysis buffer containing  50 mM Tris-HCl, pH 7.4, 150 mM 
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NaCl, 1 mM EDTA, 1% v/v Triton X-100, 0.5 mM DTT, 1% v/v protease inhibitor mixture 
(Sigma-Aldrich; P8340), 1 mM NaF, 5 mM bpVphen (Merck Millipore; 203695), 5 μM 
fenvalerate (Sigma-Aldrich; F1428), 1 mM Na3VO4, and 1% v/v phosphatase inhibitor 
mixtures 2 and 3 (Sigma-Aldrich; P5726 and P0044 respectively). The cell lysate was placed 
on ice for 10min and then centrifuged at 5000 x g for 10min at 4oC. The supernatant was 
kept at -80oC until further use. Protein concentration was determined using the PierceTM 
bicinchoninic acid assay (BCA) from ThermoFisher Scientific (23225) using bovine serum 
albumin (BSA) as protein standard.  
 
2.3. Western Blot 
Western blotting was performed using the NuPAGE electrophoresis system and buffers 
(Invitrogen) according to the manufacturer’s instructions and protein bands were visualised 
using ECLTM Prime from GE Healthcare (RPN2232) as we have described previously [10], 
[11], [25]. The following antibodies were used in the present study: rabbit anti-phospho-
p44/p42 ERK1/2 (Thr-202/Tyr-204; 9101), rabbit anti-p44/p42 (total-ERK1/2; 9102), rabbit 
anti-phospho-PLCγ1 (Tyr783; 2821), rabbit anti-phospho-PKD/PKCμ (Ser744/748; 2054), 
rabbit anti-Na+-K+-ATPase (3010) all from New England Biolabs. Monoclonal anti-PLCγ1 
(total-PLCγ1; sc-374467) and monoclonal anti-PKCα (sc-8393) were from Santa Cruz 
Biotechnology. Rabbit anti-TRPC3 (NBP2-32258) was from Novus Biologicals. Monoclonal 
anti-NCX1 was from Swant (R3F1) and monoclonal anti-GAPDH (ab8245) was from Abcam 
Labs. Densitometric quantification of protein levels was achieved by scanning films and 
determining the optical densities of the bands of interest using ImageJ 1.46r (National 
Institutes of Health) as we have described previously [11], [25]. The optical densities of the 
proteins of interest were normalised against the appropriate loading control and fold changes 
versus the ratio value of the unstimulated control, arbitrarily set as 1, are shown as 
described previously [11], [25]. 
2.4. Immunoprecipitation 
Immunoprecipitation of NCX1 from HUVECs was achieved as we previously reported [11], 
[25]. In brief, protein A-agarose beads from Roche Life Science (11-719-408-001) were 
washed with ice-cold PBS twice and then incubated with 10 μl anti-NCX1 (Swant) antibody 
for 1h at 4oC. The antibody-conjugated beads were then washed twice with ice-cold PBS 
and added to the corresponding cell lysates. After overnight incubation at 4oC, beads were 
washed twice in lysis buffer and once with PBS and complexed proteins were detached by 
boiling the beads in electrophoresis loading buffer at 95oC for 5min. In the case of the 
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immunoprecipitation experiment described in Figure 10G the NCX1 antibody was from 
Cohesion Biosciences (CPA2077) due to unavailability of the antibody from Swant. 
2.5. PKCα translocation assay 
Translocation of PKCα to the plasma membrane in response to VEGF was determined by 
isolating crude membrane fractions as we have described previously [10], [11]. Briefly, 
HUVECs were challenged with 50ng/ml of VEGF for 10min in the presence of TRPC3 
inhibitors or vehicle. The cells were scraped off in 1ml of ice-cold Triton X-free lysis buffer, 
lysed by passing 20 times through a 21-gauge needle and sonicated for 20sec with 1min 
intervals. All procedures were carried out on ice. The cell suspension was centrifuged for 
5min at 5000 x g and the supernatant was diluted with lysis buffer to 10ml total volume. The 
sample was then placed in the appropriate ultracentrifugation tubes (Beckman) and spun for 
1h at 100,000 x gav in a Ti-70 Ti rotor (Beckman). The cytosolic fraction in the supernatant 
was removed and the whole membrane fraction was re-suspended by repeated pipetting in 
75μl western blot loading buffer at 95oC. The purity of cytosolic versus membrane fractions 
was assessed by western blot for Na+-K+-ATPase or GAPDH as markers membrane or 
cytosolic markers respectively. PKCα translocation was also determined by western blot. It 
should be noted that due to extensive dilution of the cell lysate in order to achieve the 
minimum safety fill volumes of the centrifugation tubes, PKCα levels in the cytosolic fraction 
could not be determined. 
2.6. siRNA Transfection 
HUVECs were transfected with ON-TARGETplus SMARTpool siRNA duplexes against 
TRPC3 (L-006509), NCX1 (L-007620) or non-targeting siRNA (D-001206) from 
ThermoFisher Scientific, using OligofectamineTM (12252011, Invitrogen) as the transfectant 
as we have previously extensively described [10], [11], [25]. The TRPC3 siRNA pool 
targeted the following sequences: GGAAGGACCUAGGGAAUAC, 
GGUCUGGGUUCUUGGAAUG, CGGAAGCUCUCCAUGCAAU, 
GAGCAGACCAUAGCUAUCA. The NCX1 siRNA duplexes targeted the following 
sequences: GAAAUGUUAUCGUUCCAUA, GCAGAAGCAUCCAGAUAAA, 
GCAGACGCCUCCAUAGGUA, GUGAGGAUCUGGAAUGAAA and non-targeting siRNA 
was against these sequences: UAGCGACUAAACACAUCAA, 
UAAGGCUAUGAAGAGAUAC, AUGUAUUGGCCUGUAUUAG, 
AUGAACGUGAAUUGCUCAA. NCX1 knockdown was determined from HUVECs plated in 
T-75 flasks and transfected in parallel. In the experiments where HUVECs were co-
transfected with TRPC3 and NCX1 siRNA duplexes the single- transfection samples were 
also co-transfected with the appropriate amount of non-targeting control siRNA. 
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2.7. Intracellular Ca2+ Measurement Assays  
Measurements of [Ca2+]i were performed using the Fluo-4NW (Molecular Probes
TM, F36206) 
fluorescent Ca2+ indicator, according to the manufacturer’s instructions as we have 
described previously [10], [11], [25]. HUVECs were plated at a density of approximately 
1x104 cell/well into flat clear-bottomed black-walled 96 well plates (Corning®, 3603) in 
complete HUVEC medium.  The next day the medium was removed; HUVECs were washed 
twice with PBS and loaded with Fluo-4NW at 37oC, in the dark in Hanks’ balanced salt 
solution (HBSS), supplemented with 20 mM HEPES, pH 7.4, in the presence of 2.5mM 
probenecid in order to facilitate dye retention. Both HBSS and probenecid were provided 
with the Fluo-4NW kit (Molecular ProbesTM, F36206). After 45min, equal volumes of HBSS 
containing inhibitors or vehicle were added to the corresponding wells and HUVECs were 
incubated for further 15min. Subsequently, the cell plate was transferred to the assay 
chamber of the FLIPR Tetra High-Throughput Cellular Screening System (Molecular 
Devices) and the cells were challenged for 10min with either 50ng/ml VEGF or 100μM OAG 
in HBSS or HBSS and vehicle alone, as appropriate. The contents of the plate were mixed 
once and the fluorescence intensity emitted by Fluo-4NW (excitation 485nm, emission 
525nm) was measured immediately thereafter for every 2sec. Raw fluorescence data at 
each time point (F) were normalised by dividing them with the average value of background 
fluorescence (Fo) obtained for each individual well by taking 10 measurements prior to 
stimulant addition. All treatments were in triplicate and Ca2+ responses were assessed 
concurrently on the same plate 
2.8. Intracellular Na+ Measurement Assays 
Intracellular Na+ was measured in intact HUVECs loaded the fluorescent indicator Asante 
NaTRIUM Green-2 - AM (ANG-2) from TEFlabs (3502). HUVECs (1x104/well) plated into flat 
clear-bottomed black-walled 96 well plates (Corning®, 3603), as for the Ca2+ assays, were 
loaded with 5μM ANG-2 in HBSS (GIBCO, 14025092) containing 0.1% v/v Pluronic® F-127 
(Sigma-Aldrich, P2443) at 37oC in the dark. After 45min the loading solution was removed, 
cells were washed twice with HBSS and then vehicles or drugs in HBSS were added. After a 
further 15min incubation at 37oC, the plate was transferred into the assay chamber of the 
FLIPR Tetra High-Throughput Cellular Screening System (Molecular Devices) and OAG at a 
final concentration of 100μM, or HBSS alone were added to the corresponding wells. After a 
short mix step changes in ANG-2 fluorescence were monitored immediately every 2sec for a 
total of 10min with excitation wavelength of 485nm and emission wavelength of 525nm at 
37oC. Equal ANG-2 loading for each experimental condition was assured by obtaining an 
end-point fluorescent reading (Exc 485nm, Emm 525nm) prior stimulation. Fluorescence (F) at 
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each time point was normalised by the average of 10 background fluorescent readings taken 
prior to stimulation (F0), as described for the Ca
2+ experiments above. All of the experimental 
conditions were in triplicate and assayed simultaneously.  
2.9. Tubulogenesis Assays 
HUVEC tubular differentiation on ECM extracts was assessed according to our previous 
publications [10], [11], [25] with minor modifications. Briefly, 24 well plates were coated with 
250μl phenol red-free, growth factor reduced MatrigelTM (BD Biosciences, 356231) for 1h at 
37oC. Subsequently, 2.5 x 104 HUVECs in phenol red-free Opti-MEM® (GIBCO, 11058021) 
where applied to each well. Where appropriate, VEGF (50ng/ml final concentration) or OAG 
(100μM final concentration) along with TRPC3 inhibitors, reverse-mode NCX inhibitors, or 
vehicle were also added. The cells were then placed in a humidified incubator at 37oC and 
5% CO2 for 16h in the case of VEGF or 4h in the case of OAG. At the end of the experiment 
bright-field images were captured with an Olympus LX70 microscope from five random fields 
of view per sample at ×10 magnification. We opted for a much shorter incubation period for 
the OAG experiments given that it’s reported half-life in living cells is 40min [43]. HUVECs 
transfected with NCX1 or TRPC3 siRNA were plated on MatrigelTM at the same density 
(2.5x104 cells/well) as the inhibitor experiments 48h post-transfection and challenged with 
VEGF or OAG for 4h as above. Tubule length for each sample was quantified using ImageJ 
1.46r (National Institutes of Health) and was expressed as fold of the tubule length of the 
unstimulated control sample arbitrarily set to 1.  
2.10. Statistical analysis 
We determined statistical significance using one- or two-way analysis of variance (ANOVA) 
and Tukey's post hoc test with the GraphPad Prism 5 software, as appropriate. Values of p < 
0.05 were deemed significant. The data are expressed as the means ± S.E 
 
3.  RESULTS 
3.1.  TRPC3 activity is required for VEGF-induced ERK1/2 phosphorylation 
First we investigated whether the specific TRPC3 inhibitor Pyr3 [26] inhibited VEGF-induced 
ERK1/2 phosphorylation, as we have reported for reverse-mode NCX inhibitors and siRNA 
[11]. VEGF stimulation (50ng/ml) of serum-starved HUVECs led to a substantial increase in 
ERK1/2 phosphorylation, peaking between 5 to 10 minutes of stimulation and reverting to 
baseline levels after 30min. Preincubation of cells with the TRPC3 inhibitor Pyr3 (10µM) 
suppressed VEGF-induced ERK1/2 activation at all time points tested when compared with 
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the vehicle-treated (0.5% v/v Me2SO) controls (Fig. 1A). The effect of Pyr3 on ERK1/2 
activation was also dose-dependent (Fig. 1B). Serum-starved HUVECs challenged with 
50ng/ml VEGF for 10 min exhibited a 14.40 ± 0.71 - fold normalized phospho-ERK1/2 ratio 
increase versus the untreated control ratio (arbitrarily set to 1). Pretreatment with 1, 3 or 
10µM Pyr3 significantly suppressed ERK1/2 activation for all conditions tested to 9.37 ± 
1.50, 7.38 ± 0.87 - and 0.84 ± 0.31 - fold of the unstimulated control phospho-ERK1/2 ratio, 
p = 0.045, p = 0.022, p = 0.003, n = 3 for all,  respectively (Fig. 1C). Importantly, Pyr3 
pretreatment did not affect PLCγ1 phosphorylation at a site (Tyr783) directly phosphorylated 
by activated VEGFR2 [5], suggesting that TRPC3 inhibition does not affect VEGFR2 activity 
and indicating that cells under all conditions tested were equally stimulated and viable (Fig 
1B and 1C). 
  In order to further confirm TRPC3 involvement in VEGF-induced ERK1/2 activation, 
we employed a second TRPC3 inhibitor, Pyr10 [27]. Pyr10 also attenuated VEGF-induced 
ERK1/2 activation at all time points tested when compared with controls (Fig. 1D). Unlike 
Pyr3, Pyr10 did not have an effect on ERK1/2 phosphorylation at lower concentrations (1 or 
3µM) (Fig. 1E and 1F). Conversely, 10µM Pyr10 suppressed ERK1/2 activation from 16.50 ± 
3.71 -fold to 2.07 ± 0.41 – fold of the unstimulated control ratio, arbitrarily set to 1, p = 0.025, 
n = 3 (Fig. 1E and 1F). Pretreatment of HUVECs with Pyr10 also did not affect PLCγ1 
phosphorylation in response to VEGF, indicating, as in the case of Pyr3, that Pyr10 did not 
directly influence VEGFR2 activity at any of the tested concentrations (Fig. 1E and 1F) or 
non-specifically the ability of HUVECs to transduce VEGF signals. 
 Next we sought to confirm our pharmacological data employing a gene-knockdown 
strategy. Transfection of HUVECs with TRPC3-targeting siRNA duplexes significantly 
blunted the observed ERK1/2 activation when compared with cells transfected with control 
non-targeting siRNA from 20.50 ± 1.69 -fold to 10.09 ± 1.25 -fold of the unstimulated control, 
p = 0.004, n = 3 (Fig. 1G and 1H). TRPC3 protein knock down was confirmed by western 
blot and shown to be approximately 50% of controls at the protein level (Fig. 1G to 1I).  
Taken together our results, so far, suggest that TRPC3 activity is vital for ERK1/2 
activation by VEGF, as we have previously shown for VGSCs [10] and NCX1 [11], implying 
that collectively these proteins could be part of a functional signalling complex. 
3.2. TRPC3 inhibitors attenuate PKCα activation in response to VEGF   
We have previously reported that VGSC and reverse-mode NCX1 activities modulated 
ERK1/2 phosphorylation by influencing the activity of the Ca2+-sensitive PKC isoform PKCα 
[10], [11]. Thus, we next investigated whether TRPC3 activity also affected VEGF-induced 
PKCα activation. PKCµ/PKD is known to be phosphorylated in response to VEGF and to be 
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required for VEGF-induced ERK1/2 phosphorylation [28]. Moreover, in HUVEC, PKCµ/PKD 
was phosphorylated at Ser744/748 in a PKCα-dependent manner [28]. Thus, initially we 
monitored PKCµ/PKD phosphorylation at these sites, as a surrogate of PKCα activity in 
intact VEGF-stimulated HUVECs. PKCµ/PKD phosphorylation significantly increased after 
5min of VEGF addition in concert with ERK1/2 activation (Fig. 2A), as we have previously 
reported [10]. Preincubation of HUVECs with Pyr3 (10µM) significantly decreased 
phosphorylation of PKCμ/PKD and ERK1/2 (from 4.90 ± 0.07 to 0.66 ± 0.009 - folds of 
control, p = 0.011, n = 3 (Fig. 2B) and from 17.65 ± 1.35 to 3.11 ± 0.85 – folds of control, p = 
0.010, n = 3 (Fig. 2C) respectively). Pyr3 preincubation also significantly suppressed 
PKCμ/PKD and ERK1/2 phosphorylation after 10 and 15min of VEGF stimulation (Fig. 2A-
2C).  
Pyr3 has been reported to suppress CRAC-mediated Ca2+ influx non-specifically at 
similar concentrations to those inhibiting TRPC3 [27].  In order to exclude that the observed 
effect of Pyr3 on ERK1/2 and PKCμ/PKD phosporylation was due to inhibition of CRAC 
channels we included in our experiments the CRAC channel inhibitor Pyr6 [27]. 
Preincubation with Pyr6 (10µM) significantly suppressed VEGF-induced ERK1/2 activation 
from 17.65±1.35 to 10.88±1.90 – normalised fold of the unstimulated control, p = 0.008, n = 
3, albeit with less potency than Pyr3 (Fir. 2A, 2C). Crucially, preincubation with Pyr6 did not 
significantly affect phospho-PKCμ/PKD levels after 5min and surprisingly significantly 
increased PKCμ/PKD phosphorylation after 10min and 15min of stimulation with VEGF (Fig. 
2A and Fig. 2C), suggesting that unlike Pyr3 its effect on ERK1/2 activation was not via 
PKCα.  
Interestingly, the effect of TRPC3 inhibition on phospho-PKCµ appears to be to some 
extent temporal in nature. After 15min phospho-PKCµ levels, although still significantly 
suppressed, are less decreased when compared to the 5min samples (Fig. 2A and Fig. 2B). 
A number of PKC isoforms can phosphorylate PKCµ and in addition to PKCα, PKCβ2 and 
PKCδ are reportedly activated by VEGF [28], [29]. It is plausible that at a later stage another 
PKC isoform, possible Ca2+ insensitive, could as a feedback mechanism compensate and 
phosphorylate PKCµ to some extent without affecting ERK1/2. Although this is an interesting 
that merits investigation the focus of the present study is on the ERK1/2 pathway and 
investigating this is beyond the scope of our study.  
As an additional control, we tested that the pharmacological compounds employed 
did not inhibit non-specifically the intracellular enzymes that translate the Ca2+ signal into 
ERK1/2 activation. This was achieved by bypassing VEGF receptor-mediated Ca2+ influx by 
stimulating HUVECs with the Ca2+ ionophore ionomycin (1µM for 5min), a treatment that we 
have previously shown resulted in robust ERK1/2 activation [10], [25].  Preincubation of 
HUVECs with the maximum concentrations of Pyr3 (10μM) or Pyr10 (10μM) we have 
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employed in our study did not have an apparent effect on ionomycin-induced ERK1/2 
activation (Fig. 2D), suggesting that their effect was primarily on Ca2+ influx. Moreover, this 
experiment also indicated that treatment of HUVECs with Pyr3 or Pyr10 did not affect their 
ability to activate ERK1/2 non-specifically by for example affecting their viability. Conversely, 
10μM Pyr6 had an observable impact on ERK1/2 activation in response to ionomycin (Fig. 
2D). This indicated that the Pyr6 effect on ERK1/2 phosphorylation was probably not Ca2+-
influx mediated and possibly non-specific. 
We further investigated PKCα activation in VEGF-stimulated HUVECs by monitoring 
its translocation to the plasma membrane, a process that correlates with activity [29]. Crude 
membranes and cytosolic fractions of VEGF-stimulated HUVECs in the presence or absence 
of TRPC3 inhibitors, as indicated, were separated by ultracentrifugation and the prevalence 
of PKCα in each fraction was tested by western blot, as previously described [10], [11]. Na+-
K+-ATPase and GAPDH protein levels served as markers of membrane and cytosolic 
fractions respectively and confirmed separation of the fractions.  VEGF stimulation resulted 
in a 7.27 ± 0.64 – fold increase of normalised PKCα levels compared with control conditions. 
Pretreatment with Pyr3 (3μM) or Pyr10 (10μM) resulted in a marked decrease in PKCα 
translocation to 1.72 ± 0.33 and 2.52 ± 0.47 – fold of the control, p = 0.002 and p = 0.003 
respectively, n = 3 for both (Fig. 2E and Fig. 2F).  
In order to further confirm that TRPC3 activity is upstream of PKC activation, as our 
finding in Fig. 2E suggests we stimulated HUVECs with PMA. As we have previously shown 
[10], PMA application was sufficient to activate ERK1/2 and preincubation with Pyr3 (10µM) 
or Pyr10 (10µM) did not have an apparent effect on PMA – induced ERK1/2 phosphorylation 
(Fig. 2G)  
Collectively, our results indicate that inhibition of TRPC3 activity suppressed VEGF-
induced ERK1/2 activation by modulating PKCα activation, as we have previously reported 
for NCX [11], further supporting our hypothesis that these proteins are functionally coupled.   
3.3.  Effect of TRPC3 inhibitors on VEGF-induced Ca2+ transients     
We next investigated the effect of the TRPC3 inhibitors Pyr3 and Pyr10 on VEGF-induced 
Ca2+ transients. Serum-starved HUVECs stimulated with VEGF exhibited a rapid increase in 
fluorescence of the intracellular Ca2+ indicator Fluo-4NW that peaked at ∼80sec, as we have 
previously reported [10], [11]. Cytosolic steady-state Ca2+ levels remained significantly 
higher than the baseline for the duration of the experiment (250sec; Fig. 3A). Preincubation 
of HUVECs for 15min with the TRPC3 inhibitors Pyr3 (3μM) or Pyr10 (10μM) prior to VEGF 
stimulation resulted in a partial decrease in the Ca2+ response. In particular, Pyr3 (3μM) and 
Pyr10 (10μM) suppressed the Ca2+ signal in VEGF-stimulated HUVECs, quantified as area 
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under the curve, from 8.08 ± 0.72 – fold of the unstimulated control (arbitrarily set to 1) to  
6.08 ± 0.17 - fold and 5.92 ± 0.16 – fold, p = 0.027 and p = 0.015  respectively, n = 3 in 
triplicate for all conditions (Fig. 3B). 
3.4. Effect of TRPC3 inhibitors and siRNA on HUVEC tubular differentiation  
HUVEC tubular differentiation on extracellular matrix components was disrupted by TRPC3 
inhibitors in a dose-dependent manner. Pyr3 (3μM) significantly reduced tubule formation in 
the presence of VEGF from 1.64 ± 0.6 - fold to 0.92 ± 0.010 - fold of the unstimulated 
control, p = 0.005, n = 3 in duplicate (arbitrarily set to 1; Fig. 4A and Fig. 4B). In the absence 
of VEGF, 3μM Pyr3 also reduced tubule length to 0.84 ± 0.05 – fold of the control; however, 
the effect was not statistically significant. A higher concentration of Pyr3 (10μM) completely 
abolished HUVEC tubular differentiation both in the presence or absence of VEGF (Fig. 4A 
and Fig. 4B). Similarly, a second TRPC3 inhibitor, Pyr10 at 3μM or 10μM significantly 
attenuated EC tubule length from 1.64 ± 0.6 – fold to 1.29 ± 0.04 – fold, p = 0.025 and 0.97 ± 
0.11 p = 0.013 – fold of the unstimulated control respectively, n = 3 in duplicate for both (Fig. 
4A and Fig. 4B). Pyr10 at 10μM also had a significant effect on HUVEC tubulogenesis at 
basal levels reducing tubule length to 0.77±0.06 – fold of the unstimulated control, p = 0.031, 
n = 3 in duplicate. Interestingly, Pyr10 at a concentration that did not affect ERK1/2 
activation in the short-term (up to 30min) signalling assays (3µM; Fig. 1E) significantly 
inhibited HUVEC tubular differentiation. This is not entirely surprising since the tubular 
differentiation assays lasted longer (16h) and as such are not directly comparable with the 
signalling assays.  
 Targeting TRPC3 expression in HUVECs with siRNA also blunted HUVEC tubular 
differentiation confirming our pharmacological data. Specifically, VEGF stimulation of 
HUVECs transfected with control non-targeting siRNA resulted in increased tubule length to 
1.54 ± 0.04 – fold of the unstimulated control and knocking down TRPC3 expression 
suppressed HUVEC tubular differentiation to 0.74 ± 0.08 – fold, p = 0.004, n = 3 in duplicate 
(Fig. 4C and Fig. 4D). At basal levels, TRPC3 knockdown also significantly reduced cord 
formation to 0.45 ± 0.04 – fold of the unstimulated control, p = 0.003, n = 3 in duplicate. 
Taken together our results suggest that TRPC3 activity is required for HUVEC 
tubular differentiation on extracellular matrix components as others have previously reported 
for the HUVEC-derived cell line EA.hy926 [17] and as we have shown for NCX [11]. 
3.5. The cell-permeable DAG analogue OAG activates ERK1/2 in HUVECs in a Ca2+-
dependent manner  
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TRPC3 channels are directly activated by diacylglycerol (DAG) generated through PLC-
dependent mechanisms downstream of receptor tyrosine kinases (RTKs) or G-protein 
coupled receptors (GPCRs) [30], [31]. The effect of DAG on TRPC3 can be mimicked by 
exogenously applying its cell-permeable analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) [30]. 
Thus, in order to further confirm that TRPC3 was implicated in VEGF-induced ERK1/2 
activation, we investigated whether the direct activation of TRPC3 by OAG was sufficient to 
activate ERK1/2 in HUVECs. 
Indeed, stimulating HUVECs with OAG (100μM) for 5min was sufficient to robustly 
induce ERK1/2 phosphorylation (Fig. 5A). Loading HUVECs with the “fast” Ca2+ chelator 
BAPTA-AM suppressed ERK1/2 phosphorylation, suggesting that OAG-induced activation of 
ERK1/2 was Ca2+-sensitive. Conversely, EGTA-AM, a “slow” Ca2+ chelator that binds Ca2+ 
with the same affinity as BAPTA-AM, but does not affect local Ca2+ transients within 100nm 
of the Ca2+ source [32] did not have an observable impact on OAG-induced ERK1/2 
phosphorylation, as we have reported for VEGF [10]. HUVEC stimulation by OAG in a 
nominal Ca2+-free physiological medium resulted in a substantial reduction in phospho-
ERK1/2 levels compared with controls (Fig. 5B), indicating that Ca2+ influx was required for 
ERK1/2 activation by OAG. 
 We further tested whether influx of extracellular Ca2+, as opposed to Ca2+ release 
from internal stores was involved in OAG-induced ERK1/2 phosphorylation by using 
thapsigargin (TG), an inhibitor of the sarcoendoplasmic reticulum Ca2+-ATPase (SERCA). 
We have previously reported that challenging HUVECs with TG (4μM) resulted in a rapid 
and robust increase of [Ca2+]i in the presence of extracellular Ca
2+, peaking within 2min and 
remaining at this level thereafter, due to leak of Ca2+ from the ER and subsequent activation 
of CRAC [11]. As we reported previously [11], TG alone had no effect on the levels of 
phospho-ERK1/2 irrespective of the presence of Ca2+ in the extracellular medium in 
unstimulated HUVECs (Fig. 5C). In contrast, when OAG (100μM) was added 2min after the 
application of TG, at the peak of the Ca2+ signal [11], ERK1/2 phosphorylation was 
attenuated in the absence of extracellular Ca2+ (Fig. 5C) As shown in Fig. 5B extracellular 
Ca2+ was required for OAG-induced ERK1/2 phosphorylation (Fig. 5C). Thus, similarly to our 
findings for VEGF [11], influx of extracellular Ca2+ (rather than release of Ca2+ from the 
internal stores) appeared to be essential for ERK1/2 phosphorylation by OAG. 
 As in the case of VEGF-induced ERK1/2 activation, phosphorylation of ERK1/2 in 
response to OAG required PKC activity, since the broad spectrum PKC inhibitor of classical 
and novel PKCs (Gӧ6983) dose-dependently suppressed OAG-induced ERK1/2 activation 
(Fig. 5D). Thus, OAG application was sufficient to induce ERK1/2 activation in HUVECs and 
this required Ca2+ influx from the extracellular milieu and PKC activity. Moreover, our 
14 
 
experiment with TG suggested, as we reported for VEGF [11], that the Ca2+ influx pathway 
controlling ERK1/2 activation was distinct from CRAC. 
3.6. TRPC3 activity is required for OAG-induced ERK1/2 phosphorylation  
We next directly tested our hypothesis that OAG-induced ERK1/2 phosphorylation was due 
to TRPC3 activation. Stimulation of serum-starved HUVECs with OAG (100μM) for 5min 
resulted in a robust increase of ERK1/2 phosphorylation to 18.91 ± 1.70 - fold of the 
unstimulated control (Fig. 6A and Fig. 6B), a level comparable with that observed upon 
VEGF stimulation under similar conditions (Fig. 1C). Preincubation of the cells with the 
TRPC3 inhibitor Pyr3 significantly attenuated ERK1/2 phosphorylation to 8.05 ± 1.82 – fold, 
p = 0.001 and 2.96 ± 1.03 – fold, p = 0.001 of the unstimulated control for 3 and 10μM Pyr3 
respectively, n = 3 for both (Fig. 6B).  Targeting TRPC3 protein expression using siRNA-
mediated knockdown also suppressed OAG-induced ERK1/2 activation (Fig. 6C). In 
particular, OAG-induced ERK1/2 phosphorylation was blunted significantly from 13.01 ± 1.77 
– to 6.70 ± 1.10 – fold of unstimulated control, p = 0.011, n = 3 (Fig. 3D). TRPC3 protein 
knock-down was assessed with western blot and found to be around 50% (Fig. 6C and Fig. 
6E). 
In cardiac cells, TRPC3 activity reportedly depolarises the plasma membrane and 
results in Ca2+ influx via voltage-gated Ca2+ channels (VGCCs) [33]. Preincubating HUVECs 
with the VGCC inhibitor nifedipine had no apparent effect on OAG-induced ERK1/2 
activation (Fig. 6F). Consequently, we inferred that in HUVECs TRPC3 activity influenced 
Ca2+ influx independently of VGCC activity.  
3.7. Reverse-mode NCX activity is required for OAG-induced ERK1/2 phosphorylation   
We have previously reported that reverse-mode NCX activity modulates VEGF-induced 
ERK1/2 activation in a PKCα-dependent manner [11], as shown here for TRPC3. Thus, we 
next investigated whether reverse-mode NCX was also involved in ERK1/2 phosphorylation 
in response to OAG, further supporting our implied assumption that NCX and TRPC3 are 
functionally coupled and operate in concert. 
 Preincubation of HUVECs with the reverse-mode inhibitor SN-6 (10μM) suppressed 
OAG-induced ERK1/2 activation in a time-dependent manner (Fig. 7A). Furthermore, a 
second reverse-mode NCX inhibitor, SEA0400, dose-dependently blunted ERK1/2 
phosphorylation in response to OAG (Fig. 7B). Specifically, preincubation of HUVECs with 
0.5μM or 1μM SEA0400 significantly reduced OAG-induced ERK1/2 activation from 7.32 ± 
0.97 - fold of the unstimulated control (arbitrarily set to 1) to 2.66 ± 0.51, p = 0.005 - and 1.03 
± 0.70, p = 0.001 - fold respectively, n = 3 for both (Fig. 7C). A lower concentration of 
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SEA0400 (0.1μM) also reduced ERK1/2 phosphorylation to 4.39 ± 1.58- fold of the control 
but the effect was variable and not statistically significant, p = 0.22, n = 3 (Fig. 7C).   
Knocking-down NCX1 protein expression employing siRNA also attenuated OAG-
induced ERK1/2 phosphorylation, thus providing independent support of our 
pharmacological data (Fig. 7D). In HUVECs loaded with control non-targeting siRNA, OAG 
increased ERK1/2 activation to 11.27 ± 1.16 – fold of the unstimulated control. The response 
was significantly attenuated in HUVECs where NCX1 expression was targeted by siRNAs to 
6.20 ± 1.03 – fold of the unstimulated control, p = 0.010, n = 3 (Fig. 7E). NCX1 protein 
knockdown was confirmed in matching transfection experiments (Fig. 7F) and was 
approximately 50% at the protein level (Fig. 7G), as previously reported [11], [25].  
We then investigated, whether blocking TRPC3 or NCX activities using 
pharmacological inhibitors affected Ca2+ transients in response to OAG.  OAG application 
resulted in a rapid increase in the emitted fluorescence of the Ca2+-sensitive indicator Fluo-
4NW, peaking within around 2 min and remaining significantly higher than the control levels 
for the duration of the experiment (10min; Fig. 7H).  Preincubation of HUVECs with the 
TRPC3 inhibitors Pyr3 (3μM) or Pyr10 (10μM) significantly attenuated the bulk Ca2+ 
response to OAG measured as the area under the curve of the emitted fluorescence for 
each experimental condition (Fig. 7H and Fig. 7IH). In particular, OAG application increased 
the Ca2+ response to 9.25 ± 1.73 – fold of the control level (arbitrarily set to 1), whilst Pyr3 
and Pyr10 significantly blunted the response to 2.98 ± 0.69, p = 0.022 – fold and 2.00 ± 0.51, 
p = 0.013 – fold of the control respectively, n = 3 in triplicate for all conditions (Fig. 7I).  
Similar to TRPC3 inhibitors, preincubation with the reverse-mode NCX inhibitors SN-6 
(10μM) or SEA0400 (1μM) significantly suppressed the Ca2+ signal in OAG-stimulated 
HUVECs quantified as area under the curve (Fig. 7H and Fig. 7I). SEA0400 and SN-6 
suppressed OAG induced Ca2+ transients from 9.69 ± 1.00 – fold of unstimulated control 
(arbitrarily set to 1) to 2.91 ± 0.51, p = 0.018 – fold and 3.34 ± 0.35, p = 0.018 - fold 
respectively, n = 3 in triplicate (Fig. 7I). 
Therefore, taken together, our results suggest that TRPC3 and NCX activities were 
required for OAG – induced Ca2+ signalling, possibly working in concert. . 
3.8. TRPC3 activity regulates OAG-induced signalling by modulating Na+ influx  
Given that TRPC3 is a non-selective cation channel and both TRPC3 and NCX activities 
were required for OAG-induced signalling, we postulated that the effect of TRPC3 could be 
due to Na+ influx and subsequent reversal of NCX leading to Ca2+ influx. We tested this by 
monitoring the effects of inhibitors of TRPC3 and reverse-mode NCX on intracellular [Na+] in 
response to OAG using the cell permeable fluorescent Na+ indicator ANG-2. Challenging 
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HUVECs loaded with ANG-2 with OAG resulted in an increase in the emitted fluorescence 
that plateaued within approximately 250sec and remained significantly higher than the 
unstimulated control level for the duration of the experiment (10min; Fig 8A). Preincubating 
HUVECs with the reverse-mode NCX inhibitors SN-6 (10μM) or SEA0400 (1μM) modestly 
increased the bulk Na+ signal, measured as the area under the curved of the normalised 
emitted fluorescence from 6.51 ± 0.75 – fold to 7.45 ± 0.55 – fold and 7.39 ± 0.43 – fold of 
the unstimulated control (arbitrarily set to 1), respectively (Fig. 8B). The effect of reverse-
mode NCX inhibitors on [Na+] was not significant; p = 0.22 and p = 0.26 respectively, n = 3 in 
triplicate for both. Conversely, preincubation of HUVECs with Pyr3 (3μM) or Pyr10 (10μM) 
significantly attenuated the Na+ signal in response to OAG (Fig. 8A). In particular, Pyr3 and 
Pyr10 suppressed the total Na+ response, measured as the area under the curve of the 
emitted ANG-2 fluorescence over time, from 6.51 ± 0.75 – fold of the unstimulated control 
(set to 1) to 1.83 ± 0.38, p = 0.021 - fold and 2.23 ± 0.42, p = 0.033 - fold respectively, n = 3 
in triplicate for both (Fig. 8B).  
We next investigated whether acutely loading HUVECs with Na+ by inhibiting the 
Na+-K+-ATPase with ouabain and thus promoting reverse-mode NCX, augmented OAG-
induced ERK1/2 activation, as we reported for VEGF [11] or thrombin stimulation [25]. 
Preincubation of serum-starved HUVECs with ouabain (100μM for 1min) prior to brief 
stimulation with OAG (100μM for 2min) significantly enhanced ERK1/2 phosphorylation from 
1.83 ± 0.45 – fold of unstimulated control to 6.81 ± 1.07 – fold, p = 0.014, n = 3 (Fig. 8C and 
Fig. 8D).  The reverse-mode NCX inhibitor SN-6 cancelled out the effect of ouabain on OAG-
induced ERK1/2 activation, suggesting that it was probably via induction of reverse-mode 
NCX (Fig. 8C). 
 We then tested the effect of the TRPC3 inhibitor Pyr3 (3μM) on OAG-induced 
ERK1/2 phosphorylation in the presence of ouabain, as described in Fig. 8C. Pretreatment 
of HUVECs with ouabain enhanced ERK1/2 phosphorylation in response to brief OAG 
challenge as expected; however, Pyr3, unlike SN-6 (Fig. 8C), had no apparent effect on 
ERK1/2 activation in the presence of ouabain (Fig. 8E).  
Consequently, taken together these experimental data suggest that TRPC3 activity 
was primarily required for increasing [Na+] in response to OAG, presumably resulting in Ca2+ 
influx via reverse-mode NCX. Moreover, in HUVECs already loaded with Na+ (by inhibiting 
the Na+-K+-ATPase with ouabain) TRPC3 activity, unlike NCX activity, was dispensable for 
OAG-induced ERK1/2 phosphorylation.  
3.9. OAG-induced HUVEC tubular differentiation requires TRPC3 and NCX activities  
17 
 
 We investigated whether OAG stimulation of HUVECs, similar to VEGF, was sufficient to 
induce tubular differentiation on extracellular matrix components and whether ERK1/2, 
TRPC3 and NCX activities were involved. Application of OAG for 4h increased HUVEC 
tubule length to 1.54 ± 0.04 – fold of the unstimulated control (set to 1; Fig. 9A and Fig. 9B). 
The reverse-mode NCX inhibitor SEA0400 reduced tubule length from 1.54 ± 0.04 - fold to 
1.06 ± 0.05, p = 0.004 – fold or 0.91 ± 0.04, p = 0.001 – fold of control at 0.5μM or 1μM 
respectively, n = 3 in duplicate for both (Fig. 9A and Fig. 9B). The TRPC3 inhibitor Pyr3 
(3μM) significantly reduced HUVEC tubule length to 0.77 ± 0.07 – fold of the unstimulated 
control, p = 0.001, n = 3 in duplicate, whilst 10μM Pyr3 completely abolished the response 
(Fig. 9A and Fig. 9B). The effect of SEA0400 and Pyr3 was probably due to inhibition of 
ERK1/2 phosphorylation since an inhibitor of the ERK1/2 pathway (PD98050 at 10μM) also 
significantly reduced HUVEC normalized tubule length to 0.84 ± 0.05 – fold of the 
unstimulated control, p = 0.001, n = 3 in duplicate. SEA0400 (1μM), Pyr3 (3μM) and 
PD98050 (10μM) also modestly (albeit significantly) suppressed HUVEC tubulogenesis at 
basal levels to 0.85 ± 0.04, p = 0.030, 0.75 ± 0.05, p = 0.016, and 0.79 ± 0.09, p = 0.015 – 
fold of the unstimulated control respectively, n = 3 in duplicate for all conditions (Fig. 9A and 
Fig. 9B). A higher concentration of Pyr3 (10μM), as in the case of VEGF stimulation (Figure 
4), completely abolished HUVEC tubule formation (Fig. 9A).  
Similar results were obtained when NCX1 and TRPC3 expression was targeted with 
siRNA.  In HUVECs transfected with control non-targeting siRNA, OAG enhanced tubule 
formation  to 1.55 ± 0.06 – fold of the unstimulated control whilst  with  siRNA targeting 
TRPC3 or NCX1 expression it was significantly reduced to 0.86 ± 0.04, p = 0.001 – fold and 
1.04 ± 0.5, p = 0.010 – fold respectively, n = 3 in duplicate for both (Fig. 9C and Fig. 9D).  
TRPC3 knockdown also significantly suppressed HUVEC tubule formation to 0.66 ± 0.07 – 
fold in the absence of OAG stimulation, p = 0.018, n = 3 in duplicate, as we observed for 
VEGF (Fig. 4D), whilst targeting NCX1 had no significant effect (Fig. 9C and Fig. 9D).   
3.10. Simultaneous Inhibition of TRPC3 and NCX1 activities has an additive effect on 
VEGF - and OAG – induced ERK1/2 activation. 
Finally, we directly assessed whether TRPC3 and NCX1 activities had an additive effect on 
ERK1/2 phosphorylation in response to VEGF, as our work so far suggests and as would 
have been expected if they work in concert. HUVECs were preincubated with Pyr3 (3µM) or 
SN-6 (5µM), concentrations we have shown supressed around 50% of VEGF – induced 
ERK1/2 activation (Fig. 1B and [10] respectively), alone or in combination. As expected, 
Pyr3 or SN-6 at these concentrations reduced VEGF-induced ERK1/2 activation to around 
50% of the control (Fig. 10A and Fig. 10B). Conversely, combining Pyr3 and SN-6 
treatments resulted in significant attenuation of ERK1/2 activation in comparison to each 
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treatment alone. Specifically, combining Pyr3 (3µM) and SN-6 (5µM) reduced normalized 
ERK1/2 phosphorylation to 2.65 ± 0.20 fold of the unstimulated control from 8.58 ± 0.43, p = 
0.02, n = 3; and 8.09 ± 0.26, p = 0.01, n = 3, for each treatment alone (Fig. 10A and Fig. 
10B).  
 Combining Pyr3 and SN-6 treatments similarly to VEGF also had an additive effect in 
OAG – stimulated HUVECs. Whilst, Pyr3 (3µM) or SN-6 (5µM) pretreatment attenuated 
OAG – induced ERK1/2 activation by around 50% to 7.10 ± 0.50 – and 6.60 ± 0.79 – fold of 
control respectively, their combination further suppressed ERK1/2 activation to 1.80 ± 0.49 – 
fold of control (p = 0.009 and p = 0.011 respectively, n = 3 for both; Fig. 10C and Fig. 10D).  
 The pharmacological data were also confirmed by combining siRNA treatments 
targeting TRPC3 and NCX1 gene expression. Knocking down TRPC3 or NCX1 expression 
with siRNA resulted in around 50% reduction in ERK1/2 phosphorylation as expected (Fig. 
1G and [10]). Combining siRNA treatment had a significantly more pronounced effect on 
VEGF – induced ERK1/2 phosphorylation. Specifically, TRPC3 siRNA reduced ERK1/2 
activation to 10.40 ± 0.58 – fold of control, whilst NCX1 siRNA reduced ERK1/2 activation to 
10.27±0.48 – fold (Fig. 10E and Fig. 10F). Combining siRNA treatments significantly 
reduced ERK1/2 phosphorylation further to 4.98 ± 0.34 fold of control (p = 0.006 and p = 
0.004 when compared to the single treatments, n = 3 for both; Fig. 10E and Fig. 10F). 
Knocking down NCX1 did not appear to have an effect on TRPC3 protein expression for the 
48h duration of the experiment (Fig. 10E, top panel). Similarly, knocking down TRPC3 did 
not appear to influence NCX1 protein expression (Fig. 10G). It should be noted that in all 
conditions HUVECs were transfected with 200nM siRNA in total (See also Section 2.6). 
Additionally, a different antibody against NCX1 was used in Fig. 10G than the one used for 
the experiment shown in Fig. 7F (see also Section 2.4.), due to unavailability of the original 
Antibody from Swant. The new antibody recognised only one NCX1 band, suggesting that 
the lower molecular weight band observed in Fig. 7F and in our previous work, [10] and [25], 
possibly corresponded to a proteolytic fragment. 
 Collectively, since the effect of treatments was additive, this line of investigation 
supports our hypothesis that TRPC3 and NCX1 work in concert to activate ERK1/2 
downstream to VEGF 
4. DISCUSSION 
TRPC3s are non-selective cation channels that require DAG (generated by PLCs 
downstream of RTKs and GPCRs) for maximal activity [30], [31]. TRPC3s are known to be 
expressed in HUVECs [34] and were activated downstream of VEGF when heterologously 
co-expressed with VEGFR2 in HEK293 cells [14]. Moreover, TRPC3 activity in coronary 
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arterial EC enhanced monocyte adhesion when challenged with TNFα in vitro [35]. Also, in 
mice where TRPC3 was genetically overexpressed specifically in the endothelium, 
atherosclerotic lesion sizes were increased [36]. TRPC3 activity has also been directly 
implicated in tubular differentiation in the HUVEC-derived cell line EA.hy926 [17]. Moreover, 
TRPC3-mediated Na+ influx has been shown to result in Ca2+ influx indirectly by reversing 
the bi-directional transporter NCX first in HEK293 cells [24] and later in a number of 
additional experimental systems, including intact hearts [37], smooth muscle cells [38] and 
platelets [39]. Nonetheless, despite the well-documented role of TRPC3 in endothelial 
pathophysiology, precisely how its activity influences downstream signalling remains largely 
unexplored. Additionally, to the best of our knowledge, coupling between TRPC3 and NCX 
has not been previously reported in the endothelium. Here, we provide evidence that 
TRPC3s, downstream of VEGFR2 and PLCγ1, regulates ERK1/2 activation and 
angiogenesis by modulating PKCα activity, probably in concert with reverse-mode NCX. 
Furthermore, we demonstrate that direct activation of TRPC3s by the cell-permeable DAG 
analogue OAG was sufficient to activate ERK1/2 and promote EC tubular differentiation in 
vitro and this also required reverse-mode NCX activity, further supporting our hypothesis that 
TRPC3s and NCX1 are functionally coupled in HUVECs. More specifically: 
4.1.  Effect of TRPC3 activity on ERK1/2 activation and [Ca2+]i transients in response to 
VEGF   
The TRPC3 inhibitors Pyr3 and Pyr10 or TRPC3 protein depletion with siRNA blunted 
VEGF-induced ERK1/2 activation (Section 3.1.; Fig. 1), as we have previously reported for 
NCX [11] and VGSCs [10]. Similar to our previous reports [10], [11]. TRPC3 activity was 
required for PKCα activation in response to VEGF, as exemplified by PKCα translocation to 
the membrane fraction and PKD/PKCμ phosphorylation (Section 3.2.;.Fig. 2), a process 
known to precede ERK1/2 activation [28]. The inhibitors of TRPC3 (Pyr3 or Pyr10) also 
suppressed bulk Ca2+ transients in HUVECs challenged with VEGF by approximately 25% 
(Section 3.3.; Fig. 3), as we have reported with reverse-mode NCX inhibitors [11]. TRPC3 
inhibition did not completely abolish the VEGF-induced Ca2+ response in HUVECs, however, 
this is not surprising since a number of receptor – or store - operated channels have been 
shown to regulate Ca2+ influx in ECs [13], [40]. Nonetheless, our results indicate that TRPC3 
activity, possibly coupled with reverse-mode NCX [11] conduct at least a significant 
proportion of the Ca2+ signal required for VEGF-induced ERK1/2 activation in a spatially-
restricted manner. Additionally, TRPC3 activity was also required for HUVEC tubular 
differentiation (Section 3.4.; .Fig. 4).  
Collectively, our present findings and our previous studies [10], [11], suggest that 
TRPC3, NCX1 and VGSCs form a functionally coupled signalling complex to modulate 
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VEGF-induced Ca2+ influx, PKCα activation, ERK1/2 phosphorylation and ultimately, HUVEC 
tubular differentiation. Despite considerable focus on the role of TRPC3 activity and Ca2+ 
influx in pathophysiology, it is often overlooked that TRPC3s are non-selective cation 
channels. Furthermore, in bovine aortic EC, TRPC3s were roughly equally permeable to Na+ 
and Ca2+ with a ratio of PCa/PNa≈1.62 [41]. Consequently, since in physiological fluids, 
similar to our experimental system, extracellular [Na+] is roughly 60-fold greater than [Ca2+], 
even taking into account the higher concentration gradient for Ca2+ normally found in cells,  it 
can be expected that a substantial amount of Na+ ions will enter the cell through TRPC3. 
Indeed, in a number of systems, including HEK293 cells [24], intact hearts [37], smooth 
muscle cells [38] and platelets [39] TRPC-mediated Na+ influx was shown to result in Ca2+ 
influx indirectly by reversing NCX.  Our findings that TRPC3 activity, like reverse-mode NCX 
[11], regulated VEGF-induced ERK1/2 and PKCα activation suggest that this is also the 
case in VEGF-stimulated endothelial cells. 
4.2.  CRAC currents are not involved in acute VEGF-induced ERK1/2 phosphorylation   
The TRPC3 inhibitor Pyr3, used in our experiments, had minimal impact on the activities of 
other closely related TRPC isoforms [26]. However, Pyr3 reportedly inhibits CRAC currents 
non-specifically in mast cells with the same potency as TRPC3 activity [27]. In HUVECs, 
CRAC currents are primarily mediated by the plasma membrane Orai1 and the ER STIM1 
subunits of the CRAC channel [40] and Orai1 activity has been implicated in the angiogenic 
response of HUVECs to VEGF [18]. We further corroborated TRPC3 involvement by 
including in our experiments a second inhibitor more specific for TRPC3 than CRAC, Pyr10 
[27]; and siRNA. Furthermore, others have shown that knocking down Orai1 (the pore-
forming constituent of CRAC) had no effect on HUVEC tubular differentiation [17]. 
Nonetheless, we directly tested the involvement of Ca2+ influx by CRAC channels on VEGF-
induced ERK1/2 activation by using the CRAC inhibitor Pyr6 that had minimal effect on 
TRPC3 activity in TRPC3-overexpressing HEK293 cells [27]. Pyr6 suppressed VEGF-
induced ERK1/2 activation with less potency than TRPC3 inhibitors without reducing 
PKD/PKCμ phosphorylation (Section 3.2.; Fig. 2A and Fig. 2C), a surrogate marker of PKCα 
activity [28]. Moreover, Pyr6, unlike Pyr3 or Pyr10, also inhibited ERK1/2 activation in 
HUVECs stimulated with the Ca2+ ionophore ionomycin (Section 3.2.; Fig. 2D), suggesting 
that its effect was independent of Ca2+ influx and possibly non-specific.  
Initiating CRAC with thapsigargin in the presence of extracellular Ca2+ did not 
activate ERK1/2 (Section 3.5.; Fig. 5C). Conversely, application of ionomycin, expected to 
increase [Ca2+]i uniformly across the plasma membrane did (Fig. 2D). Additionally, our 
previously published work suggested that ERK1/2 activation in response to VEGF required 
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localised Ca2+ rise [10]. Thus, it is conceivable that in VEGF-stimulated ECs the CRAC 
current and the Ca2+ signal required for ERK1/2 phosphorylation constitute two functionally 
and spatially distinct Ca2+ microdomains. This is supported by the finding that CRAC-
mediated Ca2+ influx did not occur uniformly across the plasma membrane of HeLa cells but 
at “hotspots” where the plasma membrane and the ER are in close proximity [42]. 
Nevertheless, our work does not conclusively preclude Orai1/CRAC involvement in 
angiogenesis and VEGF signalling, since long term CRAC inhibition could modulate 
angiogenesis indirectly by regulating the filling of the internal Ca2+ stores.  
4.3.  The DAG analogue OAG activates ERK1/2 in a TRPC3- and NCX1-dependent manner 
The implied functional association of NCX with TRPC3 was further investigated by the 
application of the cell-permeable DAG analogue OAG. OAG directly activates the 
TRPC3/TRPC6/TRPC7 subfamily of TRPC channels [30], [31] and in human microvascular 
ECs it produced non-specific cation currents similar to those activated by VEGF [14]. 
 We report here that OAG on its own was sufficient to substantially elevate 
phosphoERK1/2 levels in ECs.  Our results (Section 3.5.; Fig. 5A-C), suggest, as we have 
reported for VEGF [10], that local Ca2+ influx as opposed to global Ca2+ is required for this. 
Moreover, our experimental data using a nominal Ca2+-free physiological medium (Section 
3.5.; Fig. 5B), or thapsigargin (Fig. 5C). similar to our previous report for VEGF [11], indicate 
that Ca2+ influx rather than Ca2+ release from the internal stores was critical for OAG-induced 
ERK1/2 activation. Again, as for VEGF [10], ERK1/2 phosphorylation in response to OAG 
required PKC activity. Taken together our findings suggest that OAG and VEGF-induced 
ERK1/2 activation share crucial similarities; particularly their dependence on Ca2+ influx and 
PKC activity and consequently OAG could be used to study aspects of VEGF signalling. 
 TRPC3 activity was also required for OAG-induced ERK1/2 activation. TRPC3 
inhibitors (Section 3.6.; Fig. 6A) or siRNA (Section 3.6.; Fig. 6C) reduced OAG-induced 
ERK1/2 phosphorylation. In cardiomyocytes Na+-influx via TRPC3 resulted indirectly in Ca2+ 
influx via VGCCs upon plasma membrane depolarisation [33]. This appears not to be the 
case in ECs, since, as we showed previously for VEGF [10], an inhibitor of VGCCs had no 
obvious effect on OAG-induced ERK1/2 phosphorylation (Section 3.6.; Fig. 6F).  
 Our hypothesis that TRPC3 and NCX1 are functionally coupled and regulate ERK1/2 
signalling in HUVECs was further validated by our finding that treatment with reverse-mode 
NCX inhibitors (Section 3.7.; Fig. 7A to Fig. 7C) or NCX1-targeting siRNA (Section 3.7.; Fig. 
7D and Fig. 7E) also significantly attenuated OAG-induced ERK1/2 phosphorylation, as we 
have previously shown for VEGF [11]. This was further corroborated by our finding that 
combining pharmacological inhibitors targeting TRPC3 and NCX1 activities or siRNA 
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treatments targeting their expression had an additive effect on ERK1/2 activation by VEGF 
or OAG (Fig. 10).  
4.4.  Effect of TRPC3 and reverse-mode NCX activities on OAG-induced Ca2+ and Na+ 
transients   
In platelets activation of DAG-sensitive TRPC channels increased [Na+]i, whilst subsequent 
Ca2+ influx was mediated via reverse-mode NCX [39].  We investigated whether this was 
also applicable to OAG-stimulated ECs. Indeed, OAG, as previously reported for 
microvascular ECs [14], significantly increased [Ca2+]i in HUVECs, whilst pretreatment with 
both TRPC3 (Fig. 7H) or reverse-mode NCX inhibitors (Fig. 7H), significantly blunted the 
Ca2+ signal, suggesting that TRPC3 and NCX constitute the primary Ca2+-influx routes 
activated by OAG. Crucially, when we measured intracellular [Na+] under identical 
conditions, we observed a significant increase in intracellular Na+ upon OAG application that 
was suppressed by TRPC3 inhibitors (Section 3.8.; Fig. 8A). Conversely, in samples pre-
treated with reverse-mode NCX inhibitors intracellular [Na+] was marginally, although not 
statistically significantly, higher than the OAG-treated control (Fig. 8A and Fig. 8B). It is 
tempting to speculate that this was due to reduced Na+ extrusion after inhibition of reverse-
mode NCX, however further experimentation is required to support this hypothesis. Even if 
this is not the case our results clearly demonstrate that reverse-mode NCX activity did not 
increase intracellular Na+. We further explored the role of intracellular Na+ by monitoring 
ERK1/2 activation in response to OAG in ECs loaded with Na+ by briefly inhibiting the Na+-
K+-ATPase with ouabain as we did previously for VEGF [11] and thrombin [25]. Ouabain 
significantly amplified OAG-induced ERK1/2 phosphorylation and the response was blunted 
by SN-6, signifying that presumably reverse-mode NCX induction by high intracellular Na+ 
was probably involved (Section 3.8.; Fig. 8C).  On the contrary, pre-treatment of HUVECs 
with Pyr3, an inhibitor of TRPC3, had no apparent effect on the enhanced OAG-induced 
ERK1/2 phosphorylation observed in ouabain-treated cells (Section 3.8.; Fig. 8E). This 
experiment suggests that once HUVECs are loaded with Na+ via another route (inhibition of 
the Na+-K+-ATPase in this instance) that can promote reverse-mode NCX, then TRPC3 
activity is dispensable for OAG-induced ERK1/2 phosphorylation.   
Collectively, this line of investigation corroborated our hypothesis that in stimulated 
HUVECs Na+ influx was primarily mediated by TRPC3 whilst Ca2+ entry occurred via 
subsequent induction of reverse-mode NCX. This is supported by our findings that (i) 
although both TRPC3 and NCX inhibitors suppressed OAG-induced Ca2+ influx only TRPC3 
inhibitors attenuated Na+ transients and (ii) once cells were loaded with Na+ TRPC3 activity, 
(unlike reverse-mode NCX) was superfluous for OAG-induced ERK1/2 activation.  
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We also attempted to monitor whole-cell intracellular Na+ in VEGF-stimulated 
HUVECs. Unlike our experiments with OAG, in this instance we could not detect reliably an 
increase in intracellular Na+ since the response was variable and often barely detectable (not 
shown). Thus, although VEGF-induced Ca2+ transients are more prominent than those in 
response to OAG, the global Na+ signal appears to be significantly more modest, at least 
when measured with our experimental setup. This is not entirely surprising, since as 
discussed in Section 4.1., other Ca2+ influx mechanisms also contribute to the global Ca2+ 
transients observed in response to VEGF. Interestingly, reverse-mode NCX [11] and TRPC3 
inhibitors (Fig.3A and Fig. 3B) both suppressed approximately 20% of the total VEGF-
induced Ca2+ signal. This is comparable to the global Ca2+ signal (approximately 25% 
increase from baseline) we observed in response to OAG (Fig. 7H). Notably, in both cases, 
despite the difference in the magnitude of global [Ca2+]i, the extent of maximal ERK1/2 
phosphorylation was comparable (Fig.1 and Fig. 6), further supporting our hypothesis that 
only a proportion of global Ca2+ entry by VEGF is associated with ERK1/2 activation in a 
spatially-restricted manner. Thus although in the case of VEGF the Ca2+ response is more 
prominent,  it does not follow that the Na+ response would also be more pronounced since 
additional ionic mechanisms can contribute to the global Ca2+ rise. Moreover, it is 
conceivable that in the case of VEGF, generated DAG could be rapidly degraded and/or 
sequestered, consequently shutting down or confining the Na+ signal. On the contrary, since 
OAG was reportedly a poor substrate for the lipases that break down DAG [43] it is expected 
to have a longer half-life in cells hence magnifying the bulk Na+ transient measured in or 
experiments. This is probable since our experiments with the “slow” Ca2+ chelator EGTA-AM, 
indicated that Ca2+-sensitive ERK1/2 activation occurred within 100nm of the source of Ca2+ 
entry. Consequently, the associated Na+ signal should likewise be spatially restricted. Little 
is known about Na+ signalling in ECs, however, such a mechanism has been reported in 
pancreatic islet β cells where Na+ influx via plasma membrane VGSCs resulted in significant 
Na+ uptake by the mitochondria [44]. Possibly measuring Na+ signals in single cells could 
provide better sensitivity. Despite the failure to measure [Na+] in VEGF-stimulated HUVECs 
with our experimental setup, our work strongly suggests that Na+ signals could be also 
playing a crucial role in endothelial pathophysiology and their significance merits further 
investigation.  
4.5.  OAG promotes HUVEC tubular differentiation by activating TRPC3 and NCX   
We show here for the first time that OAG application promotes HUVEC tubular differentiation 
in an in vitro surrogate assay for neo-angiogenesis [45]. ERK1/2 activation is crucial for 
endothelial tubular differentiation [8] and indeed an inhibitor of the ERK1/2 pathway 
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suppressed OAG-induced tubulogenesis. EC tubule formation was also observed when 
control cells were plated on ECM in the absence of OAG. This was also significantly 
suppressed by the ERK1/2 pathway inhibitor (Section 3.9.; Fig. 9). Crucially, both TRPC3 
and NCX1 inhibitors and siRNA significantly suppressed OAG-induced HUVEC tubular 
differentiation, presumably by modulating ERK1/2 activation. Interestingly, both TRPC3 
inhibitors and siRNA appear to inhibit HUVEC tubulogenesis more potently than the ERK1/2 
pathway inhibitor or reverse-mode NCX inhibitors and siRNA. Although this could be due to 
different pharmacokinetics (stability and/or cellular uptake) or more efficient TRPC3 knock 
down, it is plausible that TRPC3 activity could be modulating additional pro-angiogenic 
signalling pathways. This has been demonstrated in cardiomyocytes where TRPC3 
modulated both Ca2+ influx via VGCCs and nuclear factor of activated T-cells (NFAT) 
activation by distinct ionic mechanisms [33].  
4.6. Limitations of the study 
Our work does not preclude the involvement of other channels of the Trp gene family in the 
EC angiogenic responses observed. Indeed, TRPC1 [46] and TRPC6 [15], [16] activities 
have also been implicated in angiogenesis. TRPC3 is known to complex with other TRPC 
isoforms, forming functional non-selective cation channels, including TRPC1 [47] and 
TRPC6 [48]. Since the composition of native TRPC channels in ECs is unknown, the 
involvement of other TRPC channels in the macromolecular complex that could potentially 
reverse the mode of NCX in our experimental setting cannot be excluded. Determining the 
exact subunit composition of the TRPC3 channel contributing to angiogenesis in HUVECs 
merits further investigation. However, this is beyond the scope of the present study. 
Moreover, it is conceivable that other Na+ influx mechanisms could also become functionally 
associated with NCX to modulate endothelial signalling, depending on the stimulus/insult. 
For example, in astrocytes acidification led to Na+ entry via the Na+/HCO3− co-transporter 
resulting in reversal of NCX [49]. This mechanism could be applicable in tumour 
angiogenesis where hypoxia results in considerable acidosis.  
 Recently, Pyr3 at low micromolar concentrations, as those used in the present study, 
was shown to inhibit the activity of TWIK – related K+ channels (TREK); [50]. In the 
endothelium TREK channels are believed to be activated by stretch and participate in the 
maintenance of vascular tone [51]. Given that our experiments were performed under static 
conditions, in all probability TREK channels were not involved.  However, TREK involvement 
should be considered, if Pyr3 was used to inhibit in vivo angiogenesis. 
Interestingly, similar to our previous work with VEGF [11] and thrombin [25], it 
appears that TRPC3 and reverse-mode NCX inhibitors have an impact on ERK1/2 
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phosphorylation at baseline. This phenomenon is difficult to reliably quantify since baseline 
ERK1/2 phosphorylation levels are approximately 15-fold less than the maximal activation 
observed upon stimulation with VEGF or OAG, as judged by densitometry. Hence its 
prominence strongly depends on technical factors such as film exposure and identical 
protein loading between experimental repeats. TRPC3 is known to possess some basal 
activity in vitro in the absence of stimulation [52]. It is probable that this is sufficient to induce 
some baseline ERK1/2 activation and this could occur via reverse-mode NCX and inhibited 
by TRPC3 and NCX1 siRNA and inhibitors. Despite the technical difficulties, exploring  basal 
ERK1/2 activity and its associated mechanisms merits further investigation, particularly since 
ECs are known to be tonically active in vivo. Nonetheless, elucidating the mechanism(s) 
contributing to basal ERK1/2 activation in HUVECs is beyond the scope of the present study. 
We also observed baseline inhibition of HUVEC tubulogenesis by TRPC3 inhibitors 
and siRNA. This is in agreement with studies by others in the HUVEC-derived cell line 
EA.hy926 [17].  It is well documented that HUVECs can form tubules on extracellular 
matrices in the absence of growth factors, probably via activation of integrin receptors which 
in turn could complex with VEGFR2 and modulate its activity [53]. It appears that basal 
tubulogenesis to some degree also required TRPC3 and reverse-mode NCX activities. 
However, the upstream activator of ECM-induced tubulogenesis has not been conclusively 
established and is beyond the scope of this study.  
5. Conclusions 
To summarise, our results are consistent with the following mechanistic model: VEGFR2 
activation by VEGF ligation leads to DAG generation via PLCγ1. Subsequent activation of 
the DAG-sensitive non-selective cation channel TRPC3 results in Na+ influx, followed by 
Ca2+ entry by the induction of reverse-mode NCX. This targets PKCα to the plasma 
membrane, where it becomes fully activated resulting in ERK1/2 phosphorylation and 
subsequent endothelial tubular differentiation and angiogenesis (Figure 10). Other 
associated mechanisms such as the membrane potential modulated by VGSCs [10], the 
Na+-K+-ATPase and Na+ uptake by the mitochondria (omitted here for simplicity) could 
further refine the angiogenic response. 
Collectively, our present work with TRPC3 and our previous studies with VGSC [10] 
and NCX [11], support the notion that Ca2+ entry via reverse-mode NCX and the associated 
ionic mechanisms play a crucial role in endothelial signalling and neo-angiogenesis in vitro. 
Very little is known about the role of stromal ionic activities in preclinical models of abnormal 
angiogenesis. Recently, Puro and colleagues elegantly measured the membrane potential 
and pharmacologically assessed the predominant ionic currents operating in actively 
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angiogenic vessels of hypoxic mouse retinas ex vivo [54]. Intriguingly, the second most 
prominent current was found to be mediated by reverse-mode NCX, followed by non-
selective cation currents, presumably conducted by TRPCs, supporting our in vitro findings 
in HUVEC It is probable that similar ionic mechanisms operate in the highly hypoxic vessels 
of solid tumours in vivo [1], [2]. We envisage that targeting the reverse-mode NCX-TRPC3 
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FIGURE LEGENDS 
Figure 1. TRPC3 activity is required for VEGF-induced ERK1/2 phosphorylation. A, 
Serum-starved HUVECs were preincubated with the specific TRPC3 inhibitor Pyr3 (10μM) or 
vehicle for 30min prior to addition of VEGF (50ng/ml) for the indicated times. ERK1/2 
activation was probed by Western blot. Membranes were subsequently stripped and re-
probed with a total-ERK1/2 antibody to ensure equal protein loading. B, The effect of Pyr3 
on PLCγ1 and ERK1/2 activation was also assessed over a range of doses in HUVECs 
stimulated for 10min with VEGF (50ng/ml). C, Normalized optical densities of the phospho-
ERK1/2 and phospho-PLCγ1 bands against the corresponding total-ERK1/2 loading 
controls. The value of the unstimulated control level (bar C) was arbitrarily set to 1 and all 
other values were calculated as fold changes  relative to bar C. Bars represent the means ± 
S.E. from n = 3 experiments. *, p < 0.05 versus the VEGF-stimulated control. A second 
specific TRPC3 inhibitor Pyr10 (10μM) also attenuated VEGF-induced ERK1/2 activation in 
a time-dependent manner (D). The effect of Pyr10 on PLCγ1 and ERK1/2 phosphorylation 
was also investigated over a range of doses (E) and quantified (F) as described in (C). Data 
are expressed as the means ± S.E. from n = 3 experiments. *, p < 0.05 versus the VEGF-
stimulated control. G, HUVECs were transfected with TRPC3-targeting or control non-
targeting siRNA duplexes. After 48h, cells were serum-starved and challenged with VEGF 
(50ng/ml) for 10min. ERK1/2 phosphorylation and TRPC3 protein levels were determined as 
described in (A). Relative optical densities of phospho-ERK1/2 (H) and TRPC3 (I) were 
assessed as in (C). Data are shown as the means ± S.E. from n = 3 experiments *, p < 0.05 
versus the VEGF-stimulated control. For (I) *, p < 0.05 versus the non-targeting siRNA-
treated control. 
Figure 2. TRPC3 activity is required for VEGF-induced PKCμ/PKD phosphorylation 
and PKCα translocation to the membrane fraction. A, Serum-starved HUVECs were 
challenged with VEGF in the presence of the TRPC3 inhibitor Pyr3 (3μM), the CRAC 
inhibitor Pyr6 (10μM) or vehicle. Phospho-PKCμ/PKD, phospho-ERK1/2 or total ERK1/2 
levels were determined by Western blot as described in Fig. 1A. Densitometric values of fold 
changes of normalized phospho-PKCμ/PKD (B) or phospho-ERK1/2 (C) ratios were 
assessed as described in Fig. 1C. Values from n=3 independent experiments are shown as 
the means ± S.E for both (B) and (C). *, p < 0.05 VEGF in the presence of Pyr3 values 
versus the VEGF-stimulated control. #, p < 0.05 VEGF in the presence of Pyr6 values versus 
the VEGF – stimulated control. D, Serum-starved HUVECs were stimulated with ionomycin 
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(1μM) for 5min in the presence of Pyr3 (10μM), Pyr10 (10μM), Pyr6 (10μM) or vehicle as 
indicated. ERK1/2 activation was evaluated by Western blot as in Fig. 1A). E, Cytosolic and 
membrane fractions from control (C) or VEGF-stimulated HUVECs in the presence or 
absence of the TRPC3 inhibitors Pyr3 (3μM) and Pyr10 (10μM), or vehicle were separated 
by ultracentrifugation. PKCα translocation to the crude membrane fraction and the presence 
of the plasma membrane marker Na+-K+-ATPase or the cytosolic marker GAPDH, were 
assessed by Western blot. F, Densitometric analysis of PKCα levels in the membrane 
fraction, normalized by optical density of  Na+-K+-ATPase in each corresponding sample are 
shown. Data are presented as the means ± S.E. and were from n = 3 experiments *, p < 
0.05 versus the VEGF-stimulated control. G, HUVECs were stimulated with the PKC 
activator PMA (1µM) for 10min in the presence of Pyr3 (10µM) or Pyr10 (10µM) as indicated, 
n = 3 independent experiments.  
Figure 3. TRPC3 inhibitors attenuate VEGF-induced Ca2+ transients. (A) Representative 
Fluo-4NW Ca2+-sensitive fluorescence of HUVECs stimulated with VEGF (50ng/ml) over 
time in the presence of TRPC3 inhibitors or vehicle are shown. VEGF was added at time 0 
and after a mix step fluorescence was measured every 2sec. Blue traces represent 
unstimulated control, red traces VEGF-stimulated cells, green traces cells preincubated with 
Pyr3 (3μM) prior to VEGF stimulation and purple traces cells preincubated with Pyr10 
(10μM) prior to VEGF stimulation. (B), Area under the curve of the Ca2+ transients shown in 
(A) calculated as fold changes in relation to the unstimulated control (arbitrarily set to 1). 
Bars represent means ± S.E. (n = 3 in triplicate). *, p < 0.05 versus VEGF-stimulated control. 
Figure 4. TRPC3 activity is required for VEGF-induced HUVEC tubular differentiation 
on ECM components. (A) HUVECs in Opti-MEM-I® medium containing 0.2% v/v FCS in 
the presence or absence of VEGF (50ng/ml) were seeded in 24-well plates coated with 
growth factor-reduced MatrigelTM. Where appropriate the indicated concentrations of the 
specific TRPC3 inhibitors Pyr3 and Pyr10 or vehicle were also included, as appropriate. 
Images from 5 random fields of view were obtained after 16h and representative images at 
10x magnification are shown for each experimental treatment. (B) Tubule length was 
quantified from the images taken in (A). Mean tubule length of the unstimulated control (C) 
was set to 1. Bars represent means ± S.E. (n = 3 in duplicate). *, p < 0.05 versus the 
corresponding control. (C) images of HUVECs transfected with control non-targeting or 
TRPC3-targeting siRNA with or without VEGF and seeded on MatrigelTM as in (A) for 4h. (D), 
quantification of tubule length from n=3 in duplicate experiments from (C) was carried out as 
described in (B) 
Figure 5. ERK1/2 activation by the diacylglycerol cell-permeable analogue 1-Oleoyl-2-
acetyl-sn-glycerol (OAG) requires extracellular Ca2+ and PKC activity. A, Serum-starved 
HUVECs were loaded with the “fast” Ca2+ chelator BAPTA-AM or with the “slow” Ca2+ 
chelator EGTA-AM for a further 20min prior to stimulation with the TRPC3 activator OAG 
(100μM) for 5min. ERK1/2 activation was assessed with Western blot as in Fig. 1A. B, 
HUVECs were serum-starved for 45min and then switched to a Ca2+-free buffer for a further 
15min prior to challenge with OAG (100μM) or vehicle for 5min. ERK1/2 phosphorylation 
was assessed by Western blot as before. C, HUVECs incubated in complete physiological 
buffer or in a medium where Ca2+ has been omitted were challenged with thapsigargin (TG) 
for 2min. Subsequently, where appropriate, cells were stimulated with OAG (100μM) for a 
further 5min. ERK1/2 phosphorylation was probed as in Fig. 1A. D, Serum-starved HUVECs 
were incubated with the indicated concentrations of the broad spectrum PKC inhibitor 
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Gӧ6983, or vehicle for 30min. Subsequently, OAG (100μM) was added to the bath and 
ERK1/2 activation was assessed as in Fig. 1A. For all the experiments n = 3 
Figure 6. TRPC3 activity was required for OAG-induced ERK1/2 activation and Ca2+ 
transients. A, HUVECs were preincubated with the indicated concentrations of the specific 
TRPC3 inhibitor Pyr3 or vehicle, for 30min, prior to stimulation with the TRPC3 activator 
OAG (100μM) for further 5min and ERK1/2 phosphorylation was determined as in Fig. 1A. B, 
The optical densities of the phospho-ERK1/2 bands were normalised with the corresponding 
total-ERK1/2 loading controls and were shown as described in Fig. 1C. Data are shown as 
the means ± S.E. from n = 3 experiments. *, p < 0.05 versus the OAG-stimulated control. C, 
Cells were transfected with control non-targeting siRNA or TRPC3-targeting siRNA (100nM 
for 48h), serum-starved and subsequently stimulated with OAG (100μM) for 5min. ERK1/2 
activation (D) and TRPC3 expression (E) were quantified by densitometry as described in 
Fig. 1C. Values are expressed as means ± S.E. from n = 3 experiments *, p < 0.05 versus 
the OAG-stimulated control for both (D) and (E). F, HUVECs were preincubated with the 
VGCC inhibitor nifedipine (1μM) prior to stimulation with OAG (100μM) and ERK1/2 
phosphorylation was determined by Western blot as described in Fig. 1A.  
Figure 7. Ca2+ influx via reverse-mode NCX is required for OAG-induced ERK1/2 
phosphorylation. A, HUVECs were preincubated with the reverse-mode NCX inhibitor SN-6 
(10μM) or vehicle for 30min and subsequently stimulated with the TRPC3 activator OAG 
(100μM) as indicated. ERK1/2 activation was assessed as in Fig. 1A.  B, HUVECs were 
incubated with the indicated concentrations of a second reverse-mode NCX inhibitor, 
SEA0400, for 30min prior to stimulation with OAG (100μM) for 5min. ERK1/2 activation was 
assessed by Western blot as before. C, Densitometric analysis of ERK1/2 phosphorylation of 
the experiments in B, was as described in Fig. 1C. Values are means ± S.E. from n = 3 
experiments *, p < 0.05 versus the OAG-stimulated control. D, HUVECs were transfected 
with control non-targeting siRNA, or NCX1-targeting siRNA and after 48h were serum-
starved and challenged with OAG (100μM) for 5min. ERK1/2 activation was determined by 
Western blot. E, ERK1/2 activation in D was quantified by densitometry as in Fig. 1C. Values 
are expressed as means ± S.E. (n = 3 in triplicate). *, p < 0.05 versus control siRNA-treated 
OAG-stimulated control. F, NCX1 protein levels in control- or NCX1-siRNA treated cells was 
determined by immunoprecipitation and subsequent Western blots of cell lysates from 
parallel transfections to those in D. Equal protein in each of the samples for 
immunoprecipitation was ensured by probing for β-actin in the input. G, Normalized optical 
densities of the NCX1 bands against the corresponding β-actin input levels of the siRNA 
transfections in F. Bars represent the means ± S.E. from n = 3 experiments. *, p < 0.05 
versus the control siRNA sample. H, HUVECs were preincubated with the reverse-mode 
NCX inhibitors SEA0400 (1μM) and SN-6 (10μM), the TRPC3 inhibitors Pyr3 (3µM) and 
Pyr10 (10µM) or vehicle prior to stimulation with OAG (100μM) as indicated. Changes in 
[Ca2+]i were determined by monitoring the emitted fluorescence over time of samples loaded 
with the Ca2+-indicator Fluo-4NW as described in the Methods section in a FLIPR – TETRA 
instrument.  Blue traces represent unstimulated cells, red traces OAG-stimulated cells, green 
traces cells preincubated with SEA0400, purple traces cells preincubated with SN-6, light 
blue traces cells preincubated with Pyr3 and orange traces cell preincubated with Pyr10 prior 
to OAG stimulation. Traces from a representative experiment are shown. I, Area under the 
curve of the experiments described in H were calculated as described in the Methods 
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section. Data are presented as means ± S.E. (n = 3 in triplicate). *, p < 0.05 versus OAG-
stimulated control.    
Figure 8. OAG-induced Na+ influx requires TRPC3 activity but is independent of 
reverse-mode NCX. A, HUVECs were loaded with the Na+ fluorescent probe Asante 
NATRIUM Green-2 (ANG-2) in complete physiological medium for 1h. After a 15min 
preincubation with the reverse-mode NCX inhibitors SEA0400 (1μM), SN-6 (10μM), Pyr3 
(3µM) or Pyr10 (10µM) cells were stimulated with the TRPC3 activator OAG (100μM) as 
indicated and fluorescence was monitored every 2sec in the FLIPR-TETRA instrument. 
Traces from a representative experiment are shown. B, The area under the curve of the Na+ 
transients in A was calculated as described in the Methods section. Values are expressed as 
means ± S.E. (n = 3 in triplicate). *, p < 0.05 versus the unstimulated control. C,  HUVECs 
were challenged with 100μM ouabain for 1min prior to the addition of OAG (100μM) for 2min 
and ERK1/2 activation was determined by Western blot as described in Figure 1. The 
indicated samples were incubated with SN-6 (10μM) for 30min prior to OAG addition. D, 
Densitometric analysis of ERK1/2 activation from the experiments in C was performed as in 
Fig. 1C. Data are shown as means ± S.E. (n = 3). *, p < 0.05 versus the OAG-stimulated 
control. E, Serum-starved HUVECs were pretreated with ouabain prior to stimulation with 
OAG as described in C. The indicated samples were pre-incubated with the TRPC3 specific 
inhibitor Pyr3 (3μM) for 30min prior to ouabain addition. ERK1/2 activation was assessed by 
Western blot. 
Figure 9. Increased HUVEC tubular differentiation in response to the DAG analogue 
OAG required TRPC3, NCX and ERK1/2 pathways activities.  (A) HUVECs in Opti-MEM-
I® medium containing 0.2% v/v FCS in the presence or absence of the TRPC3 activator 
OAG (100μM) were seeded in 24-well plates coated with growth factor-reduced MatrigelTM. 
Where appropriate the indicated concentrations of the TRPC3 inhibitor Pyr3, the reverse-
mode NCX inhibitor SEA0400, the ERK1/2 pathway inhibitor PD98050 (PD) or vehicle were 
also added as appropriate. After 4h, images from 5 random fields of view were obtained and 
representative images at 10x magnification are shown for each experimental treatment. (B) 
Quantification of tubule length from n=3 in duplicate experimental conditions as described in 
(A) were analysed as in Fig. 4B. (C) Representative images of tubule formation from 
HUVECs transfected with non-targeting (control), TRPC3 targeting (TRPC3) or NCX1 
targeting (NCX1) siRNA duplexes for 48h and subsequently seeded on MatrigelTM in the 
presence or absence of OAG as indicated for 4h are shown. (D) Quantification of HUVEC 
cord length for the experimental conditions in (C) was carried our as described above (n=3 in 
duplicate).      
Figure10. TRPC3 and NCX1 activities have an additive effect on VEGF – or OAG – 
induced ERK1/2 phosphorylation. A, HUVECs were preincubated with Pyr3 (3µM), SN-6 
(5µM), or both for 30min prior to stimulation with VEGF (50ng/ml) for 10min as indicated. 
ERK1/2 activation was assessed by western blot. B, Normalizes optical densities of the 
phospho-ERK1/2 bands from the experiments described in A. The value of the unstimulated 
control was arbitrarily set to 1. Bars represent the means ± S.E. from n = 3 experiments. *, p 
< 0.05 versus the single inhibitor treatment samples. The effect of combining treatment with 
the inhibitors Pyr3 and SN-6 was also assessed in OAG-stimulated HUVECs (C) and 
quantified (D) as in B.  Data are expressed as the means ± S.E. from n = 3 experiments. *, p 
< 0.05 versus the single inhibitor treatment samples. E, HUVECs were transfected with 
TRPC3  – targeting, NCX1 – targeting, control non-targeting siRNA duplexes, or their 
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combination, as indicated. After 48h, cells were serum-starved and challenged with VEGF 
(50ng/ml) for 10min. ERK1/2 phosphorylation and TRPC3 protein levels were determined as 
described in Figure 1A. Relative optical densities of phospho-ERK1/2 (F) for each condition 
were assessed as in (B). Data are shown as the means ± S.E. from n = 3 experiments *, p < 
0.05 versus the HUVEC samples transfected with only TRPC3 or NCX1 siRNA duplexes. G, 
NCX1 protein levels in control-, TRPC3- or NCX1-siRNA treated cells was determined by 
immunoprecipitation and subsequent Western blots of cell lysates from parallel transfections 
to those in E. 
Figure 11. Proposed mechanistic model. Numbers in parenthesis indicate proposed 
sequence of signalling events. (1) Ligation of VEGF to its major endothelial receptor 
VEGFR2 results in (2) PLCγ1 activation and generation of (3) diacylglycerol (DAG) and (3) 
inositol 1,4,5-triphosphate (IP3). Subsequently, (4) DAG complexes with and activates the 
DAG-sensitive non-selective cation channel TRPC3 leading to (5) Na+ influx followed by 
induction of (6) reverse-mode NCX and Ca2+ entry from the extracellular milieu. Increased 
[Ca2+] in the vicinity of the plasma membrane (7) targets PKCα to the membrane fraction 
where it complexes with DAG and becomes fully activated resulting in (8) ERK1/2 pathway 
activation and (9) downstream HUVEC tubular differentiation and angiogenesis. The effects 
of DAG can be also emulated by the application of the cell-permeable DAG analogue 1-
Oleoyl-2-acetyl-sn-glycerol (OAG). Concurrently, Ca2+ release from the internal stores via IP3 
receptors (IP3R) and the membrane potential (Vm) could further shape the NCX mode of 
action and/or activation and consequently the endothelial angiogenic response. Other 
associated mechanisms such as modulation of intracellular Na+ by the Na+-K+-ATPase or the 
mitochondria and/or modulation of intracellular Ca2+ by uptake by the sarcoendoplasmc 
reticulum Ca2+ ATPase (SERCA) or extrusion by the plasma membrane Ca2+ ATPase 
(PMCA) could further refine the amplitude of ERK1/2 phosphorylation   
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